Colorectal CancerNCT01555762
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
An observational study of Colorectal Cancer, run by Hoffmann-La Roche at 166 sites in France.
Trial summary
This multicenter, prospective, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in first-line therapy in elderly patients with metastatic colorectal cancer. Data will be collected from eligible patients for24 months. Read more about this study
- Who is it for?
- Ages 75 years and older
- Conditions the study is for
- Colorectal Cancer
- How many people
- 402 participants
- Where
- 166 sitesFrance
- Study dates
- 5 Mar 2012to 20 Jul 2016
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 75 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: Elderly patients with metastatic colorectal cancer initiating first-line treatment with Avastin
Who may be able to join
- Adult patients, >/= 75 years of age
- Metastatic colorectal cancer
- Initiating Avastin first-line therapy in combination with chemotherapy
Who cannot join
- Previous Avastin therapy
- Patient participating in a clinical study evaluating a cytotoxic anti-cancer therapy and/or an investigational new drug
Trial locations and contacts
166 sites in 1 country.
166 sites in 1 country
France166 sites
Ch D Abbeville; Medecine B1
Abbeville, 80142
Clinique Du Docteur Calabet; Cromg
Agen, 47000
Ch D Agen; Medecine Interne II
Agen, 47923
C.H. Du Pays D'aix En Provence Service du Dr Blanc
Aix-en-Provence, 13616
Poly Parc Rambot La Provencale; Chimiotherapie Ambulatoire
Aix-en-Provence, 13617
Chd Castelluccio; Oncologie
Ajaccio, 20176
Clinique Claude Bernard; Onco Hematologie
Albi, 81030
Chi D Alencon; Medecine Ambulatoire
Alençon, 61014
Chi D Alencon; Medecine I
Alençon, 61014
Hopital Nord; Medecine A
Amiens, 80054
Clinique De L Europe; Pmsi
Amiens, 80090
Clinique De L Europe; Radiotherapie Chimiotherapie
Amiens, 80090
Centre Hospitalier de L'Agglomeration Montargeoise; Medecine Polyvalente A Orientation Mi & Cancero
Amilly, 45200
Cham; Medecine D
Amilly, 45200
Ctre Radiotherapie Et Onco Medic
Amilly, 45200
Hotel Dieu; Medecine A
Angers, 49093
Cabinet Medical
Arras, 62000
Centre Radiotherapie Marie Curie
Arras, 62000
Ch D Ardeche Meridionale; Medecine A2
Aubenas, 07205
Ch D Auch; Med Interne Chimiotherapie
Auch, 32008
Clinique Sainte Catherine; Hopital De Semaine
Avignon, 84918
Clinique Du Docteur Maymard; Hopital De Jour Chimiotherapie
Bastia, 20200
Hopital De Falconaja Furiani; Hopital De Jour
Bastia, 20604
Centre Hospitalier de La Cote Basque; Oncologie
Bayonne, 64109
Centre Hospitalier; Hematologie-Oncologie
Beauvais, 60021
Hopital Jean Minjoz; Gastro Enterologie
Besançon, 25030
Hopital Jean Minjoz; Hopital de Jour
Besançon, 25030
HOPITAL JEAN MINJOZ; Oncologie
Besançon, 25030
Clinique Anne D Artois; Gastro Enterologie
Béthune, 62404
Clinique Champeau Mediterranee; Radiotherapie Oncologie
Béziers, 34535
Hopital Avicenne; Cancerologie
Bobigny, 93009
Clinique Tivoli; Sce Radiotherapie
Bordeaux, 33000
Polyclin Bordeaux Nord Aquitaine; Gastro Enterologie
Bordeaux, 33077
Centre Hospitalier Dr Duchenne; Hepato Gastro Enterologie
Boulogne-sur-Mer, 62321
Clinique Du Docteur Convert; Medecine
Bourg-en-Bresse, 01004
Centre Hospitalier Fleyriat; Oncologie/Hematologie
Bourg-en-Bresse, 01012
Ch De Fleyriat; Gastro Enterologie
Bourg-en-Bresse, 01012
Hopital Augustin Morvan; Federation De Cancerologie
Brest, 29200
Clinique Pasteur Lanroze; Chimiotherapie Radiotherapie
Brest, 29220
CMC de Bligny; Hopital de Jour
Briis-sous-Forges, 91640
CMC de Bligny; Oncologie Court Sejour
Briis-sous-Forges, 91640
CMC de Bligny; Oncologie SSR
Briis-sous-Forges, 91640
Ch De Brive La Gaillarde; Radiotherapie Oncologie
Brive-la-Gaillarde, 19312
Hopital Cote De Nacre; Gastro Enterologie
Caen, 14033
Infirmerie Protestante; Endos Digestive Coelioscopie
Caluire-et-Cuire, 69300
Hopital Pierre Nouveau; Medecine A
Cannes, 06400
Ch Antoine Gayraud; Oncologie
Carcassonne, 11890
Clinique Montreal; Chimiotherapie
Carcassonne
Clinique Du Parc; Hematologie
Castelnau Lez, 34170
Cabinet Medical
Challes-les-Eaux, 73190
Medipole De Savoie; Departement Oncologie
Challes-les-Eaux, 73190
Oncologie 37; Bureau
Chambray-lès-Tours, 37170
Hopital Prive Paul d Egine; Chimiotherapie Ambulatoire
Champigny-sur-Marne, 94507
Centre Hospitalier; Oncologie
Châteauroux, 36019
Ch De Cholet; Gastro Enterologie
Cholet, 49325
Pole Sante Republique;Oncologie Hematologie
Clermont-Ferrand, 63050
Hopital Louis Pasteur; Medecine A
Colmar, 68024
Polyclinique Saint Come; Hopital De Jour Oncologie
Compiègne, 60204
CH Sud Francilien; Oncologie
Corbeil-Essonnes, 91100
Ch Laennec; Medecine V
Creil, 60109
CHU Henri Mondor; Service d'Oncologie Medicale
Créteil, 94010
Ch De Dax; Radiotherapie Oncologie
Dax, 40107
Centre Leonard De Vinci;Chimiotherapie
Dechy, 59187
Centre Georges Francois Leclerc; Oncologie 3
Dijon, 21079
Hopital Victor Jousselin; Gastro Enterologie
Druex, 28102
Centre D Oncologie Dunkerquois
Dunkirk, 59240
Chi Eure Seine D Evreux; Oncologie Conventionnelle
Évreux, 27015
Clinique Pasteur; Oncologie Medicale, Hematologie
Évreux, 27025
Ch Jacques Monod;Medecine A4 B4
Flers, 61104
Chi De Frejus Saint Raphael; Hopital De Jour
Fréjus, 83608
Hopital De Freyming; Secteur 1
Freyming-Merlebach, 57804
Chi Alpes Du Sud Site De Gap; Med Interne Et Polyvalente
Gap, 05000
Centre Gastro Loire
Gien, 45 500
Hopital Nord Ouest;Gastro Enterologie
Gleizé, 69400
CH Emmanuel Rain; Oncologie
Gonesse, 95503
Hopital Prive De Chantilly; Medecine
Gouvieux Chantilly, 60500
Hopital Alpha Sante De Hayange; Medecine B
Hayange, 57701
Clinique Sainte Marguerite; Oncologie Medicale
Hyères, 83400
Polyclinique de Blois; Chimiotherapie Ambulatoire
La Chaussée-Saint-Victor, 41260
Centre Hospitalier Departemental Les Oudairies
La Roche-sur-Yon, 85925
Centre Hospitalier Saint Louis; Oncologie Medicale
La Rochelle, 17019
Hopital Albert Michallon; Oncologie
La Tronche, 38700
Hopital Albert Michallon; Radiotherapie
La Tronche, 38700
Ch De Lagny Sur Marne; Oncologie
Lagny-sur-Marne, 77405
Hopital Robert Boulin; Oncologie
Libourne, 33505
Polyclinique Du Bois; Oncologie
Lille, 59003
Polyclinique De La Louviere; Chimiotherapie
Lille, 59042
Ch De Longjumeau; Hopital De Jour Et Semaine
Longjumeau, 91161
Clinique Des 4 Pavillons; Chimiotherapie
Lormont, 33310
Hopital De La Croix Rousse;Hepato Gastro Entero
Lyon, 69317
Ctre Consultations La Sauvegarde
Lyon, 69338
Ctre Hosp St Joseph Et St Luc; Gastro Enterologie Endoscopie
Lyon, 69365
Hopital Prive Jean Mermoz; Cancerologie
Lyon, 69373
Hopital Prive Jean Mermoz; Gastro Enterologie Hepatologie
Lyon, 69373
Clin Mut De Lyon Eugene Andre; Hopital De Jour 1er B
Lyon, 69424
Hopital Edouard Herriot; Pavillon E Oncologie Medicale
Lyon, 69437
Clinique Saint Francois; Oncologie Medicale
Mainvilliers, 28301
Clinique Mutualiste Bonneveine; Oncologie Medicale
Marseille, 13008
CH Prive Clairval; Chimiotherapie Ambulatoire
Marseille, 13274
Hôpital Saint Joseph; Oncologie Medicale
Marseille, 13285
Hopital Timone Adultes; Oncologie Digestive
Marseille, 13385
Clinique Du Parc; Centre de Radiotherapie Gray
Maubeuge, 59600
Hopital Clinique Claude Bernard; Oncologie Medicale
Metz, 57000
Chra; Gastro Enterologie
Metz-Tessy, 74370
Hopital Layne; Medecine A2
Mont-de-Marsan, 40024
Hopital Layne; Medecine Ambulatoire
Mont-de-Marsan, 40024
Ch De Montauban; Medecine Interne
Montauban, 82013
Site Le Mittan; Hopital De Jour
Montbéliard, 25209
Ch De Montelimar; Gastro Enterologie Oncologie
Montélimar, 26216
Ghi Le Raincy Montfermeil; Gastro Medecine Interne
Montfermeil, 93370
Ghi Le Raincy Montfermeil; Radiotherapie Oncologie
Montfermeil, 93370
Hopital Jacques Monod; Hopital De Semaine Unite 53
Montivilliers, 76290
Clinique Clementville; Hopital De Jour
Montpellier, 34070
Hopital Saint Eloi; Hopital De Jour
Montpellier, 34295
Polyclinique Saint Roch; Hop Jour Chimio Radiotherapie
Montpellier, 34967
Centre Azureen De Cancerologie; Cons externes
Mougins, 06250
Clinique D Occitanie; Chimiotherapie Ambulatoire
Muret, 31605
Centre D'Oncologie de Gentilly; Oncology
Nancy, 54100
Polyclinique Gentilly; CHIMIOTHERAPIE AMBULATOIRE
Nancy, 54100
Polyclinique Du Languedoc; Chimiotherapie
Narbonne, 11780
Hopital Americain; Sce Oncologie
Neuilly-sur-Seine, 92200
Ctre Radiotherapie Cyr Deguergue
Nevers, 58000
Centre Antoine Lacassagne; Hopital De Jour A2
Nice, 06189
Hopital Caremeau; Gastro Enterologie
Nîmes, 30029
Hopital Prive Armand Brillard; Groupe Sein Paris Est
Nogent-sur-Marne, 94130
Polyclinique Des Murlins;Ambulatoire
Orléans, 45000
Clinique sainte marie; chimiotherapie ambulatoire
Osny, 95520
Hopital Des Diaconesses; Oncologie
Paris, 75571
Hopital Saint Antoine; Oncologie Medicale
Paris, 75571
CH Pitie Salpetriere; Hepathologie Gastro Enterologie
Paris, 75651
GH Paris Saint Joseph; Hopital De Jour Oncologie
Paris, 75674
Hopital Bichat Claude Bernard; Hepatologie Gastro Enterologie
Paris, 75877
Hop Europeen Georges Pompidou; Gastro Enterologie
Paris, 75908
HOPITAL TENON; Cancerologie Medicale
Paris, 75970
Clinique Francheville; Radiotherapie
Périgueux, 24000
Polyclinique Francheville; MED CHIMIOTHERAPIE RADIOTHERAPIE
Périgueux, 24000
Hopital Saint Jean; Hospitalisation Oncologie
Perpignan, 66046
Hopital Du Haut-Leveque; Gastro-Enterologie
Pessac, 33604
Ch Lyon Sud; Chir Visc Sect Jules Courmont
Pierre-Bénite, 69495
Ch Lyon Sud; Gastro Secteur Jules Courmont
Pierre-Bénite, 69495
Ctre Hosp Des Vals D Ardeche; Medecine C
Privas, 07007
Ch De Rambouillet; Medecine A2
Rambouillet, 78514
Ch Arrondissement De Montreuil; Medecine 1
Rang-du-Fliers, 62180
Centre Frederic Joliot Curie
Rouen, 76000
Hopital Yves Le Foll; Hematologie Oncologie
Saint-Brieuc, 22027
Ctre De Radiotherapie St Vincent
Saint-Grégoire, 35768
Clinique de L'Union; Oncologie
Saint-Jean, 31240
Memorial France Etats Unis; Hopital De Jour
Saint-Lô, 50009
Centre Joliot Curie
Saint-Martin-Boulogne, 62280
Ch De Saint Quentin; Gastro Enterologie Endoscopie
Saint-Quentin, 02321
Ch De Selestat; Medecine A
Sélestat, 67604
Centre Clinical; Oncologie Medicale
Soyaux, 16800
Hopital Broussais; Medecine 2A
St-Malo, 35403
Clinique Chir De L Orangerie; Chimiotherapie
Strasbourg, 67010
Clinique Saint Anne; Hopital De Jour
Strasbourg, 67010
Fondation Maison Sante Bagatelle; Gastro Enterologie
Talence, 33401
Hopitaux Du Leman Site Thonon; Gastro Enterologie
Thonon-les-Bains, 74203
Clinique Pasteur; Oncologie Medicale
Toulouse, 31076
Hopital Joseph Ducuing; Medecine Interne
Toulouse, 31076
Hopital Prive Du Vert Galant; Cons Specialisees
Tremblay-en-France, 93290
Ch De Valence; Medecine 6
Valence, 26953
Clinique Oceane; Medecine B
Vannes, 56001
Gh Mutualiste Les Portes Du Sud; Gastro-Enterologie
Vénissieux, 69200
Hopital Saint Nicolas; Medecine A
Verdun, 55107
Clinique De La Porte Verte; EST 3
Versailles, 78004
Hopital Prive Villeneuve d Ascq;Chimiotherapie Radiotherapie
Villeneuve-d'Ascq, 59657
About this study
Official title: Non Interventional Study Evaluating Efficacy and Safety in a Cohort of Elderly Patients of First Line Therapy With Avastin ® Regimen for Metastatic Colorectal Cancer.
This multicenter, prospective, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in first-line therapy in elderly patients with metastatic colorectal cancer. Data will be collected from eligible patients for24 months.
- Conditions
- Colorectal Cancer
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Cohort | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-Free Survival
Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Measured: From the time of first dose of study treatment to the time of disease progression or death from any cause (Up to 53 months)
Secondary outcomes (6)
Overall Survival
Overall survival was defined as the time between the treatment start date (date of the first infusion of bevacizumab) and date of all-cause death.
Measured: From the time of first dose of study treatment to the time of death from any cause (Up to 53 months)
Percentage of Participants With Bevacizumab Administration
Measured: Up to 36 months
Percentage of Participants With Adverse Events (AEs)
An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.
Measured: Up to 53 months
Percentage of Participants With Activities of Daily Living (ADL)
The Katz Activity of Daily Living (ADL) questionnaire scale contains 6 items evaluating in terms of autonomy or dependence the patient's ability to carry out basic activities of daily living (bathing, dressing, toileting, transfer, continence, feeding). Total score range 0 (low) to 6 (high). High score indicates participant is independent.
Measured: Baseline, Month 6, 12, 24
Lawton Instrumental Activities of Daily Living Score (IADL)
The Lawton Instrumental Activities of Daily Living Scale (IADL) is an appropriate instrument to assess independent living skills. The instrument is most useful for identifying how a participant is functioning at the present time and for identifying improvement or deterioration over time. There are 8 domains of function measured with the Lawton IADL scale (telephone use, shopping, cooking, housekeeping, laundry, mode of transportation, responsibility of own medications, and ability to handle finances). Participants are scored according to their level of functioning from 0 (low function, dependent) to 8 (high function, independent). Higher score for each domain represents better functional performance of the older people.
Measured: Baseline, Month 6, 12, 24
Percentage of Participants With Balducci Score
Balducci score defines an algorithm for the individual participant according to age, ADL and modified IADL 4-items scores, estimated performance status and comorbidities, particularly cardiovascular, cancer, depression or anemia. Balducci score is categorized in the following- Type 1 (Harmonious), Type 2 (Intermediate) and Type 3 (Frail). Type 1 indicates better results and Type 3 indicates worse outcomes.
Measured: Baseline, Month 6, 12, 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Mar 2012 (estimated)
- Study start5 Mar 2012
- Primary completion20 Jul 2016
- Study completion20 Jul 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 402 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01555762
- Sponsor's protocol ID
- ML27829
- Status last verified
- Feb 2019
- First submitted
- 14 Mar 2012
- Last updated
- 5 Mar 2019
- Results posted
- Yes, on ClinicalTrials.gov
Publications
Francois E, Mineur L, Deplanque G, Laplaige P, Smith D, Gourgou S, Tanang A, Ionescu-Goga M, Veerabudun K, Lelarge Y, Kim S, Rollot F. Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (>/=75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study. Clin Colorectal Cancer. 2020 Sep;19(3):e100-e109. doi: 10.1016/j.clcc.2020.02.009. Epub 2020 Apr 13.
PubMed 32299778
Study at a glance
From the registry record, last updated by the sponsor on 5 Mar 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non Interventional Study Evaluating Efficacy and Safety in a Cohort of Elderly Patients of First Line Therapy With Avastin ® Regimen for Metastatic Colorectal Cancer.
- ClinicalTrials.gov ID
- NCT01555762
- Acronym / sponsor ID
- ML27829
- Conditions
- Colorectal Cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 402 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Study start
- 5 Mar 2012 (actual)
- Primary completion
- 20 Jul 2016 (actual)
- Study completion
- 20 Jul 2016 (actual)
- First posted
- 15 Mar 2012 (estimated)
- Results
- Posted 22 Jan 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This multicenter, prospective, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in first-line therapy in elderly patients with metastatic colorectal cancer. Data will be collected from eligible patients for24 months.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cohort | – | – |
Who may qualify
- Ages
- 75 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Elderly patients with metastatic colorectal cancer initiating first-line treatment with Avastin
Key inclusion criteria (3 listed)
- Adult patients, >/= 75 years of age
- Metastatic colorectal cancer
- Initiating Avastin first-line therapy in combination with chemotherapy
Key exclusion criteria (2 listed)
- Previous Avastin therapy
- Patient participating in a clinical study evaluating a cytotoxic anti-cancer therapy and/or an investigational new drug
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Progression-Free Survival
Time frame: From the time of first dose of study treatment to the time of disease progression or death from any cause (Up to 53 months)
Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
6 secondary outcomes
Overall Survival
Time frame: From the time of first dose of study treatment to the time of death from any cause (Up to 53 months)
Percentage of Participants With Bevacizumab Administration
Time frame: Up to 36 months
Percentage of Participants With Adverse Events (AEs)
Time frame: Up to 53 months
Percentage of Participants With Activities of Daily Living (ADL)
Time frame: Baseline, Month 6, 12, 24
Lawton Instrumental Activities of Daily Living Score (IADL)
Time frame: Baseline, Month 6, 12, 24
Percentage of Participants With Balducci Score
Time frame: Baseline, Month 6, 12, 24
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Mar 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 32299778Francois E, Mineur L, Deplanque G, Laplaige P, Smith D, Gourgou S, Tanang A, Ionescu-Goga M, Veerabudun K, Lelarge Y, Kim S, Rollot F. Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (>/=75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study. Clin Colorectal Cancer. 2020 Sep;19(3):e100-e109. doi: 10.1016/j.clcc.2020.02.009. Epub 2020 Apr 13.
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
166 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Cancer, run by Hoffmann-La Roche at 166 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 166 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Jan 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-Free Survival (time frame: From the time of first dose of study treatment to the time of disease progression or death from any cause (Up to 53 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01555762, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2019.